SLC5A2 and chronic kidney disease: A secondary analysis of EMPA-KIDNEY showed that empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the trial, suggesting that albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor [101].